Abiopharma

Twin Disc, Inc. Joins Russell 2000® and Russell 3000® Indexes

Almonty Industries Joins Large-Cap Russell 1000® Index and Broad-Market Russell 3000® Index

Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer

Biohaven Advances a New Class of Precision Immunology Therapies: First MoDE Extracellular Protein Degrader, BHV-1300, Begins Phase 3 Pivotal Trial in Graves' Disease

Valmont Releases 2026 Sustainability Report

FreightCar America, Inc. Joins Russell 2000® and Russell 3000® Indexes

Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for the Treatment of Major Depressive Disorder (MDD)

Dyadic Expands IP Protection and Business Development Activities in Japan

Dyadic Expands IP Protection and Business Development Activities in Japan

Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for the Treatment of Major Depressive Disorder (MDD)